Voyager reports Q2 2026 results, sets Q4 milestones for two Alzheimer's programs
The company said tau PET imaging data for VY7523 and dosing initiation for VY1706 are both expected in the fourth quarter of 2026, with cash runway now guided into 2028.
SEC filing